focus -WSS

focus

author：Wikipedia 2025-09-28 19:44:46 Page View：33

Adam's take main illustration — Molly Ferguson/STAT

I am one week away from the launch of my weekly email newsletter! It’s called Adam’s Biotech Scorecard, and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

Do you have a biotech-related question you want me to answer in the newsletter? Send me an email at [email protected].

This week: A preview of Intra-Cellular Therapies’ Phase 3 study in major depressive disorder, and a couple of liver-disease physician perspectives on Rezdiffra, the newly approved treatment for MASH from Madrigal Pharmaceuticals.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Britney Spears to release memoir, 'The Woman In Me,' later this year
Next article： Moonlake's readout produced a cash windfall. Risks remain

comprehensive

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

One Duchenne patient's bittersweet hope for new treatment

Duchennemusculardystrophyisadevastatingdiseaseand,untilveryrecently,wasonewithoutmuchhope.WhenHawken

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

What don’t we know about an Alzheimer’s drug side effect?

Illustration:AlexHogan/STAT;Photo:EisaiviaAPSincetheFDA’sapprovaloflecanemab(marketedasLeqembi)andMe

focus

explore

comprehensive

What don’t we know about an Alzheimer’s drug side effect?